We are live on
!
Find out more
Lord, Abbett & Co Portfolio holdings
AUM
$30.6B
1-Year Est. Return
57.44%
This Fund
S&P 500
This Quarter
Est. Return
+13.24%
1 Year Est. Return
+57.44%
3 Year Est. Return
+215.76%
5 Year Est. Return
+368.6%
10 Year Est. Return
+2,376.62%
AUM
$43.9B
AUM Growth
+$2.09B
(+5%)
Cap. Flow
-$3.3B
Cap. Flow
% of AUM
-7.52%
Top 10 Holdings %
Top 10 Hldgs %
15.27%
Holding
715
New
81
Increased
209
Reduced
224
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$254M |
| 2 |
DHR.PRA
Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A
DHR.PRA
|
+$243M |
| 3 |
Tesla
TSLA
|
+$215M |
| 4 |
Parker-Hannifin
PH
|
+$181M |
| 5 |
Trade Desk
TTD
|
+$179M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Snap
SNAP
|
+$291M |
| 2 |
Meta Platforms (Facebook)
META
|
+$289M |
| 3 |
DFS
Discover Financial Services
DFS
|
+$193M |
| 4 |
XYZ
Block Inc
XYZ
|
+$173M |
| 5 |
Affirm
AFRM
|
+$162M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.77% |
| 2 | Healthcare | 13.4% |
| 3 | Financials | 12.39% |
| 4 | Consumer Discretionary | 11.56% |
| 5 | Industrials | 11.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Protagonist Therapeutics
PTGX
$8.58B
| $5.6M | 0.01% |
+163,664
| New | +$5.17M |
|
477
Bumble
BMBL
$400M
| $5.51M | 0.01% |
162,883
-1,796,268
| -92% | -$76.4M |
|
478
iHeartMedia
IHRT
$562M
| $5.48M | 0.01% |
260,652
| – | – |
|
|
LUXE
479
LuxExperience B.V.
LUXE
$1.12B
| $5.33M | 0.01% |
251,149
+65,420
| +35% | +$1.68M |
|
480
Valaris
VAL
$5.34B
| $5.3M | 0.01% |
147,251
-4,300
| -3% | -$150K |
|
481
Insmed
INSM
$21B
| $5.21M | 0.01% |
191,452
-1,823
| -0.9% | -$52.1K |
|
482
Curis
CRIS
$10.7M
| $5.17M | 0.01% |
2,715
-6,019
| -69% | -$14.3M |
|
483
Palantir
PLTR
$302B
| $5.16M | 0.01% |
283,310
-5,849,502
| -95% | -$129M |
|
484
Beam Therapeutics
BEAM
$2.67B
| $5.13M | 0.01% |
64,311
-771
| -1% | -$66K |
|
485
Treace Medical Concepts
TMCI
$298M
| $5.05M | 0.01% |
270,908
-2,624
| -1% | -$54.2K |
|
486
SI-BONE Inc
SIBN
$822M
| $5.02M | 0.01% |
226,171
-2,191
| -1% | -$47.2K |
|
487
Mastercard
MA
$501B
| $5.02M | 0.01% |
13,974
-152,423
| -92% | -$52.7M |
|
488
Salesforce
CRM
$155B
| $4.78M | 0.01% |
18,817
-2,965
| -14% | -$833K |
|
|
DOCU
489
DocuSign
DOCU
$10.7B
| $4.54M | 0.01% |
29,808
-414,849
| -93% | -$94.6M |
|
490
Vital Farms
VITL
$548M
| $4.51M | 0.01% |
+250,000
| New | +$4.41M |
|
491
ICICI Bank
IBN
$108B
| $4.43M | 0.01% |
223,948
-11,142
| -5% | -$220K |
|
492
Gossamer Bio
GOSS
$81.7M
| $4.41M | 0.01% |
+390,146
| New | +$4.63M |
|
493
Carvana
CVNA
$70.5B
| $4.23M | 0.01% |
91,220
-1,331,170
| -94% | -$73.2M |
|
494
Outfront Media
OUT
$5.54B
| $3.94M | 0.01% |
149,416
+2,844
| +2% | +$73.2K |
|
495
Pliant Therapeutics
PLRX
$64.4M
| $3.94M | 0.01% |
291,814
-2,843
| -1% | -$45.2K |
|
|
TPTX
496
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $3.72M | 0.01% |
77,915
-376,353
| -83% | -$16.8M |
|
497
TG Therapeutics
TGTX
$7.13B
| $3.71M | 0.01% |
195,212
-1,118,576
| -85% | -$29M |
|
498
Infosys
INFY
$49.8B
| $3.61M | 0.01% |
142,512
-359
| -0.3% | -$8.34K |
|
499
Neuropace
NPCE
$455M
| $3.59M | 0.01% |
355,972
-3,449
| -1% | -$44.8K |
|
500
Blink Charging
BLNK
$78.8M
| $3.47M | 0.01% |
+131,032
| New | +$4.22M |
|
Similar funds
Lord, Abbett & Co's Q4 2021 Portfolio in Review
As of Q4 2021, Lord, Abbett & Co held 715 positions worth $43.9B, up 5% from $41.8B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Lord, Abbett & Co withdrew a net $3.3B in Q4 2021, closing 119 positions and reducing 224 holdings. Its most notable exit was Snap, an estimated $291M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lord, Abbett & Co opened a new position in Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A worth $257M.
- Lord, Abbett & Co's largest Q4 2021 buy was Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A: 117,267 shares worth $257M.
- Lord, Abbett & Co added most to Pfizer in Q4 2021, an estimated $254M increase.
- Lord, Abbett & Co's biggest Q4 2021 reduction was Meta Platforms (Facebook), cutting an estimated $289M.
- Lord, Abbett & Co fully exited Snap in Q4 2021, selling an estimated $291M.
- Lord, Abbett & Co's ten largest holdings make up 15% of its $43.9B portfolio in Q4 2021.
- Lord, Abbett & Co opened 81 new positions and closed 119 in Q4 2021.
- Lord, Abbett & Co's portfolio value rose 5% quarter-over-quarter to $43.9B.
Based on Lord, Abbett & Co's 13F filing for Q4 2021, filed 11 Feb 2022.